| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 18, 2026 | UbiVac Appoints Walter J. Urba, M.D., Ph.D., to Scientific Advisory Board | World's 1st "Dark Matter" cancer vaccine shows promise as it tripled response rate and doubled overall survival in early phase combination immunotherapy clinical trial.
Former Providence Cancer Institute CMO and cancer immuno... |
| Feb 17, 2026 | Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) | Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC)
Tue, Feb 17, 2026 08:53 CET Report this content
OSLO, Norway, February 17, 2026 — Lytix Biopharma AS (“Lyt... |
| Nov 7, 2025 | Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025 | Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery
SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a ... |
| May 20, 2025 | New Study Advances Cancer Precision Therapies by Identifying Patients Who Benefit from Bexmarilimab treatment | The image shows breast cancer tissue, where the nuclei are stained dark blue, cancer cells tur-quoise, blood vessels yellow, and macrophages magenta. The green-highlighted areas indicate re-gions where genes expressed by macrophages were me... |
| Mar 27, 2025 | INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update | Company to Host Conference Call Today, March 27, at 4:30pm ET
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing tr... |
| Nov 10, 2024 | The Future of Cancer Care: AI and Yoga Unite for Patient Empowerment | In the realm of cancer care, two distinct yet powerful forces are emerging: artificial intelligence (AI) and yoga. Both are transforming the landscape of treatment and support for patients. As we stand on the brink of a new era in oncology,... |
| Nov 8, 2024 | Promising Phase Ib Data for UbiVac’s DPV-001 in Combination Immunotherapy for Head and Neck Squamous Cell Cancer | Pioneering the World's 1st Dark Matter Cancer Immunotherapy
UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival over PD-1 alone for patients with r/m head and neck cancer
The still ... |
| Nov 8, 2024 | Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024 | Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab
SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi... |
| Nov 8, 2024 | Genialis Highlights Potential of Xerna TME Panel as a Predictive Biomarker in Poster at SITC 39th Annual Meeting | With a new partnership with India-based 4baseCare, Genialis addresses the gap in data representation to ensure its AI/ML models work in more diverse populations
Over 15,000 patient samples from a dozen different tissues have been analyzed f... |
| Sep 6, 2024 | The New Frontier in Cancer Treatment: AI and Immune Phenotyping | In the battle against cancer, every tool counts. The latest weapon in this fight? Artificial intelligence. A recent study highlights the potential of Lunit SCOPE IO®, an AI-driven platform that analyzes the tumor microenvironment in biliary... |
| Sep 3, 2024 | Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR | AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guiding treatment decisions in advanced BTC
SEOUL, South Korea, Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered... |
| Apr 23, 2024 | Society for Immunotherapy of Cancer Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design | Society for Immunotherapy of Cancer Logo
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript "Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherap... |
| Feb 19, 2024 | FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor | Engineering a patient’s immune cells into cancer treatments works for treating blood cancers, but has fallen short in solid tumors—until now. An Iovance Biotherapeutics treatment employing a different type of cell has won accelerated FDA ap... |
| Feb 16, 2024 | New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC | - A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Check... |
| Nov 1, 2023 | AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023 | Six posters featuring the Lunit SCOPE suite and new insights into the tumor microenvironment are to be showcased at the SITC 2023 Annual Meeting
SEOUL, South Korea, Nov. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of A... |
| Nov 1, 2023 | I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023 | ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through th... |
| Sep 4, 2023 | ONCOS-102 mesothelioma study published in Journal for ImmunoTherapy of Cancer | ONCOS-102 mesothelioma study published in Journal for ImmunoTherapy of Cancer
Mon, Sep 04, 2023 07:00 CET Report this content ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS) rate at 30 months in first line pati... |
| Jul 5, 2023 | I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC | GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunothera... |
| Jun 15, 2023 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gynecologic Cancer | Immunotherapy is a rapidly evolving field. This guideline provides clinicians with trusted and up-to-date information with expert guidance on the nuances of the approved immunotherapy regimens.
MILWAUKEE (PRWEB) June 15, 2023
The Society fo... |
| Jun 12, 2023 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Gastrointestinal Cancer | Immunotherapy has transformed the standard of care for many gastrointestinal cancers, improving treatment responses and offering some patients prolonged survival.
MILWAUKEE (PRWEB) June 12, 2023
The Society for Immunotherapy of Cancer (SITC... |
| Feb 28, 2023 | Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates | First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
/EIN News/ -- SAN CARLOS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developin... |
| Feb 2, 2023 | Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board | Expansion of Scientific Advisory Board provides additional expertise in development capabilities
PHILADELPHIA – January 31, 2023 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing ... |
| Dec 12, 2022 | JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile | HONG KONG, Dec. 11, 2022 /PRNewswire/ -- Akeso Inc. (9926. HK) ("Akeso") today announced that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, published the mechanism of action of its Ligufalimab (AK117). Th... |
| Dec 12, 2022 | JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) mechanism shows promising antitumor efficacy and favorable safety profile | HONG KONG, Dec. 12, 2022 /PRNewswire/ -- Akeso Inc. (9926. HK) ("Akeso") today announced that the Journal for Immunotherapy of Cancer (JITC), a BMJ oncology journal, published the mechanism of action of its Ligufalimab (AK117). Th... |
| Nov 2, 2022 | Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer’s 37th Annual Meeting | “SITC is excited to incorporate these abstracts into an already impressive group of abstracts. The late-breaking abstracts will round out the content offered at the 37th Annual Meeting and highlight more cutting-edge research and data,” sai... |
| Nov 2, 2022 | Faron Announces Poster Presentation at SITC | Faron Announces Poster Presentation at SITC
Wed, Nov 02, 2022 08:00 CET Report this content
Faron Pharmaceuticals Ltd.
(“Faron or “Company”)
Faron Pharmaceuticals Announces Poster Presentation of Targeted Immunotherapy Bexmarilimab at Socie... |
| Oct 4, 2022 | The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology | "This checklist provides investigators, and other key stakeholders, a roadmap to identify and prioritize phase III clinical trials that are likely to offer the greatest benefit to patients." said SITC President Patrick Hwu, MD
MIL... |
| Sep 19, 2022 | Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium | SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Jerome Boyd-Kirk... |
| Aug 30, 2022 | Lung fluid may provide basis for cancer-treating vaccines: Israeli research
Into the Land: The Forgery Scandal | Fluid from the lungs could be used to develop new methods for diagnosing and possibly treating cancer, according to a new Israeli study.
The research found that specific peptides found in fluid from the lungs can “serve as a rich source of ... |
| Aug 3, 2022 | Society for Immunotherapy of Cancer (SITC) Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Nonmelanoma Skin Cancer | Immunotherapy is a rapidly-evolving field and many clinicians have limited experience using these agents to treat the more rare NMSCs. SITC developed this CPG because clinicians need expert guidance to interpret the nuances in the available... |
| Jun 2, 2022 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Lung Cancer and Mesothelioma | SITC Cancer Immunotherapy Guidelines logo SITC’s CPGs are recognized as the gold-standard information on the use of immunotherapy to offer improved outcomes for patients with cancer.
MILWAUKEE (PRWEB) June 02, 2022
The Society for Immunothe... |
| Feb 9, 2022 | Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers | HOUSTON and SINGAPORE, Feb. 9, 2022 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announce... |
| Jan 12, 2022 | OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy | BINYAMINA, Israel, Jan. 12, 2022 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced results from its ongoing multicenter clinical trial, PROPHETIC. These... |
| Jan 12, 2022 | OncoHost Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy | BINYAMINA, Israel, Jan. 12, 2022 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced results from its ongoing multicenter clinical trial, PROPHETIC. These... |
| Dec 2, 2021 | Highlight Therapeutics: BO-112 published in JITC | Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
Pre-clinical study data follow publication of positive Phase 2 results of BO-112 + pembrolizumab in melanoma at SITC
MADRID, ... |
| Nov 11, 2021 | Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting | - Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be demonstrated during the event in booth #423
- One immunotherapy combination study adds significant evidence for the potential value of using Lunit... |
| Nov 9, 2021 | Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer : Fierce Biotech | When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXce... |
| Oct 5, 2021 | RhoVac : presents 3-year follow-up results of the phase I/II study in prostate cancer | RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on October 5, 2021, that it has received and validated the top line results from its 3-year follow-up of the patients who took part in its phase I/II st... |
| Oct 5, 2021 | RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer | RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer Tue, Oct 05, 2021 11:31 CET
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today on October 5, 2021, that it has received... |
| Sep 16, 2021 | SITC Debuts Clinical Practice Guidelines Mobile App Focused on Immunotherapy | Cancer Immunotherapy Clinical Practice Guidelines Mobile App Screen Shots “The SITC CPG Mobile App will be a valuable resource for cancer care providers, by providing guideline information and interactive tools to help design and carry out ... |
| Sep 14, 2021 | SITC and AACR Outline Future Directions for Investigating Immune-related Adverse Events | “Just as SITC and AACR partnered to establish these recommendations, so too will multidisciplinary collaborations be critical to answering these important questions.”
MILWAUKEE (PRWEB) September 14, 2021
The Society for Immunotherapy of Can... |
| Aug 18, 2021 | OncoHost Wins Frost & Sullivan 2021 Technology Innovation Leadership Award for Excellence in Best Practices | BINYAMINA, Israel, Aug. 18, 2021 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, today announced it has been awarded this year's Best Practices Technology Innova... |
| Aug 5, 2021 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer | SITC Cancer Immunotherapy Guidelines logo “Immunotherapy fills an important unmet need for patients with urothelial cancer who are too frail or are unwilling to endure the toxicity associated with chemotherapy,” said Matthew D. Galsky, co-c... |
| Jul 20, 2021 | Roswell Park Team Shows Dendritic-Cell Vaccines Can Be Paired With Standard Therapy for Breast Cancer | Fumito Ito, MD, PhD, and colleagues have shown that dendritic-cell treatment vaccines can be combined with radiation therapy as a potential treatment for some breast cancers. "We show that these approaches, radiotherapy and intratumora... |
| Mar 31, 2021 | BLUEBIRD BIO, INC.
bluebird bio : Medigene AG - Publication of research on co-receptor independent MAGE-A4-specific T cell receptor | Planegg - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces the publication of a peer-reviewed paper entitled, 'Development of a... |
| Mar 30, 2021 | MEDIGENE AG
Medigene : Publication of research on co-receptor independent MAGE-A4-specific T cell receptor | Planegg/Martinsried - 30 March 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces the publication of a peer-reviewed paper entit... |
| Jan 7, 2021 | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy | Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy
Dan Brudzewsky, PhD
Senior Field Applications Scientist - UK & Nordics
Travis Yates, PhD
Field Applications Scientist
Tumor Mutational Burden: A Continually Evo... |
| Dec 18, 2020 | Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Effector Cell-related Adverse Events | “This is the tenth manuscript published in SITC’s Cancer Immunotherapy Guidelines series, a critically important effort to educate physicians and other health care providers, and improve outcomes for cancer patients receiving FDA-approved i... |
| Israeli scientists racing to deliver world’s 1st pill-form immunotherapy for cancer
Into the Land: The Forgery Scandal | Israeli scientists are developing an oral immunotherapy for cancer, and say they expect it to be the first such drug to become available for use.
Today there are some oral immunotherapy treatments for allergies, but not cancer immunotherapy... |
| A look at the promise of IL-15-based immunotherapies in the treatment of cancer | By Jonathan Zalevsky, PhD, Chief Research & Development Officer, Nektar Therapeutics
For decades, researchers have worked to harness the potential of the body’s immune system to fight cancer. One novel approach being explored is the use... |